Injectable peptides drugs market to reach $117.18bn by 2035
Updated
Updated · Precedence Research · May 7
Injectable peptides drugs market to reach $117.18bn by 2035
14 articles · Updated · Precedence Research · May 7
The market is forecast to grow from $53.07bn in 2026 at a 9.2% CAGR, after totaling $48.60bn in 2025, with North America holding a 40% share.
Insulin and insulin analogs led drug types in 2025 with 35%, while GLP-1 receptor agonists are projected to expand fastest at 14.5%; diabetes and obesity management accounted for 45% of applications.
Asia Pacific is expected to post the fastest regional growth at 11.5%, while AI, homecare use, online pharmacies and advances in long-acting delivery are seen accelerating development and adoption.
With AI discovering new drugs faster than ever, can regulators adapt quickly enough to ensure these treatments are actually safe?
Is the booming unregulated online peptide market the next major public health crisis in waiting?
As miracle weight-loss drugs boom, will their thousand-dollar price tags create a new era of health inequality?
How Oral GLP-1 Approvals and Asia-Pacific Expansion Are Fueling a $117 Billion Injectable Peptides Surge
Overview
The injectable peptides drug market is rapidly expanding, driven by breakthrough FDA approvals of oral GLP-1 therapies that validate the peptide pathway and broaden patient access. Rising chronic disease prevalence and an aging population fuel growing demand, prompting significant industry investments and innovations like smart autoinjectors and long-acting formulations to improve treatment adherence. The Asia-Pacific region emerges as a key growth and manufacturing hub, with local players gaining regulatory credibility. Despite challenges such as reimbursement hurdles, supply chain fragility, and high costs, strategic partnerships and advanced manufacturing investments are positioning the market for sustained growth and intense competition, especially in obesity and CNS therapies.